Estrella Immunopharma Advances EB103: First Dose Cohort in STARLIGHT-1 Trial Completed Successfully

Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW), a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers and solid tumors, has successfully completed the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. The trial, which is evaluating the safety, tolerability, and preliminary efficacy of EB103, a CD19-redirected ARTEMIS® T-cell therapy, has demonstrated promising results, paving the way for the advancement to the second dose cohort.

The first dose cohort included patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who had failed multiple prior lines of therapy. Preliminary data from this cohort demonstrated a favorable safety profile, with no dose-limiting toxicities (DLTs) or treatment-related serious adverse events (SAEs) observed. Additionally, tumor response was noted in all patients at Month 1, indicating the potential therapeutic effect of EB103.

The STARLIGHT-1 trial follows a standard 3+3 dose-escalation design, aiming to evaluate the safety profile, pharmacokinetics of EB103, and determine the Recommended Phase II Dose (RP2D). The successful completion of the first dose cohort marks a significant milestone in EB103's development program, bringing the therapy closer to determining its optimal dose and potentially differentiating it in the market due to its favorable safety profile.